SuperworthCorcept Therapeutics EPS CORT
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.42
- Latest quarter, Q2 FY26
- $0.36
- +24% on a year earlier
- Fiscal year 2025
- $0.82
- −34% on the year before
Corcept Therapeutics' earnings per share was $0.42 over the twelve months to Jun 30, 2026, down 63% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.36, up 24% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 1% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.82 | −34% |
| FY2024 | $1.24 | +31% |
| FY2023 | $0.95 | +8% |
| FY2022 | $0.88 | −1% |
| FY2021 | $0.89 | +5% |
| FY2020 | $0.85 | +9% |
| FY2019 | $0.78 | +30% |
| FY2018 | $0.60 | −41% |
| FY2017 | $1.02 | +1357% |
| FY2016 | $0.07 | n/a |
| FY2015 | −$0.07 | n/a |
| FY2014 | −$0.31 | n/a |
| FY2013 | −$0.46 | n/a |
| FY2012 | −$0.41 | n/a |
| FY2011 | −$0.40 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.36 | +24% | $0.42 | |
| Q1 FY26 | −$0.30 | −276% | $0.35 | |
| Q4 FY25 | $0.20 | −23% | $0.82 | |
| Q3 FY25 | $0.16 | −61% | $0.88 | |
| Q2 FY25 | $0.29 | −9% | $1.13 | |
| Q1 FY25 | $0.17 | −32% | $1.16 | |
| Q4 FY24 | $0.26 | −7% | $1.24 | |
| Q3 FY24 | $0.41 | +46% | $1.26 | |
| Q2 FY24 | $0.32 | +28% | $1.13 | |
| Q1 FY24 | $0.25 | +79% | $1.06 | |
| Q4 FY23 | $0.28 | +100% | $0.95 | |
| Q3 FY23 | $0.28 | −7% | $0.81 |
Against its peers
Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $1.00 |
Where Corcept Therapeutics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Corcept Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.